Advertisement

Annals of Surgical Oncology

, Volume 20, Issue 11, pp 3519–3526 | Cite as

Predicting Postoperative Morbidity Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC) with Preoperative FACT-C (Functional Assessment of Cancer Therapy) and Patient-Rated Performance Status

  • Chukwuemeka U. Ihemelandu
  • Richard McQuellon
  • Perry Shen
  • John H. Stewart
  • Konstantinos Votanopoulos
  • Edward A. Levine
Gastrointestinal Oncology

Abstract

Background

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) is associated with significant perioperative morbidity. One goal of our ongoing patient-reported health-related quality of life (HRQoL) program is to describe the prognostic value of HRQoL measures for predicting postoperative morbidity and mortality following CS+HIPEC.

Methods

A retrospective analysis of a prospectively collected clinical database for all patients treated for peritoneal carcinomatosis and who participated in our patient-reported HRQoL program from 2001 to 2011 was done. Patients completed the Functional Assessment of Cancer Therapy questionnaire plus the colon symptom subscale, in addition to the Eastern Cooperative Oncology Group (ECOG) performance status rating prior to CS+HIPEC. The trial outcome index (TOI), a specific measure of function, symptoms, and physical well being of the patient, was analyzed. The TOI is a combination of the physical and functional well being subscales + the colon-specific subscale of the FACT-C.

Results

Of 855 patients, 387 (45.2 %) participated in the HRQoL trials. Mean age was 53.3 years, and 213 (55 %) were female versus 174 (45 %) males. There were 240 patients (62 %) who had a complication versus 147 (38 %) who had no complication. A 30-day mortality rate of 7.7 % (30) was documented. Patients who suffered a 30-day postoperative mortality demonstrated a lower mean preoperative score in the FACT-C TOI 52.7 versus 61.7; P < 0.001. Independent predictors of 30-day mortality on multivariate analysis included TOI (0.05), age (0.001), and smoking (0.001). Patients with a higher TOI score were less likely to suffer a mortality (95 % CI 0.9–1.0, P = 0.05). Patients with a higher emotional well being (EWB) score were less likely to suffer a complication 0.9 (95 % CI 0.87–1.0, P = 0.04). Other independent predictors of postoperative morbidity included diabetic status (P = 0.05), ECOG performance status (0.001), and gender (0.02).

Conclusions

Preoperative HRQoL, as measured by FACT-C and ECOG performance status and added to traditional factors, helps predict postoperative morbidity and mortality following CS+HIPEC.

Keywords

Emotional Well Being Peritoneal Carcinomatosis Eastern Cooperative Oncology Group Performance Status Hyperthermic Intraperitoneal Chemotherapy Peritoneal Surface Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Stewart JH 4th, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Jones J, de Cossart L. Risk scoring in surgical patients. Br J Surg. 2003;86:149–57.CrossRefGoogle Scholar
  8. 8.
    Wakabayashi H, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Validation of risk assessment scoring systems for an audit of elective surgery for gastrointestinal cancer in elderly patients: an audit. Int J Surg. 2007;5:323–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Velanovich V. Preoperative laboratory screening based on age, gender, and concomitant medical diseases. Surgery. 1994;115:56–61.PubMedGoogle Scholar
  10. 10.
    Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: a multivariate analysis. Surgery. 1991;109:236–43.PubMedGoogle Scholar
  11. 11.
    Holloway S, Sarosi G, Kim L, Nwariaku F, O’Keefe G, Hynan L, et al. Health-related quality of life and postoperative length of stay for patients with colorectal cancer. J Surg Res. 2002;108:273–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy: A longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer. 2003;39:287–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171–5.PubMedGoogle Scholar
  16. 16.
    Saxton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg. 2011;253:1223–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Anthony T, Hynan LS, Rosen D, Kim L, Nwariaku F, Jones C, et al. The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003;238:690–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D, et al. Reliability and validity of the functional assessment of cancer therapy-colorectal(FACT-C) HRQOL instrument. Qual Life Res. 1999;8:181–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.PubMedGoogle Scholar
  20. 20.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982:5:649–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Cavaliere F, Valle M, De Simone M, Deraco M, Rossi CR, Di Filippo F, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo. 2006;20:747–50.PubMedGoogle Scholar
  23. 23.
    Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, et al. Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg. 2006;30:2025–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Ford MK, Beattie WS, Wifeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Bapoje SR, Whitaker JF, Schulz T, Chu ES, Albert RK, et al. Preoperative evaluation of the patient with pulmonary disease. Chest. 2007;132:1637–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199:S3–S10.PubMedCrossRefGoogle Scholar
  28. 28.
    Eton D, Fairclough D, Cella D, Yount S, Bonomi P, Johnson D. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Trask PC, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 2009;15:435–40.PubMedCrossRefGoogle Scholar
  30. 30.
    McQuellon R, Duckworth KE. Health-related quality of life and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Curr Probl Cancer. 2009;33:203–18.PubMedCrossRefGoogle Scholar
  31. 31.
    Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196:909–13; discussion 913–4.Google Scholar
  32. 32.
    Ware JE Jr, Kosinski M, Gandek B. SF-36R Health Survey: manual & interpretation guide. Lincoln, RI: QualityMetric Inc., 1993, 2000.Google Scholar
  33. 33.
    Shen, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.Google Scholar
  34. 34.
    Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.PubMedCrossRefGoogle Scholar
  35. 35.
    Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMedGoogle Scholar
  36. 36.
    Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer; a population base cohort study. Lancet. 1999;354:1331–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Cunningham AJ, Phillips C, Stephen J, Edmonds, C. Fighting for life: A qualitative analysis of the process of psychotherapy-assisted self-help in patients with metastatic cancer. Integr Cancer Ther. 2002;1:146–61.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Chukwuemeka U. Ihemelandu
    • 1
  • Richard McQuellon
    • 2
  • Perry Shen
    • 1
  • John H. Stewart
    • 1
  • Konstantinos Votanopoulos
    • 1
  • Edward A. Levine
    • 1
  1. 1.Section of Surgical Oncology, Department of General SurgeryWake Forest School of MedicineWinston-SalemUSA
  2. 2.Department of Internal MedicineWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations